Cylexin CY-1503 carbohydrate blocker of the cell adhesion molecule selectin data

CYTL (San Diego) announced Phase I results in a three-dose blinded study with eight volunteers enrolled at each dose, two receiving placebo. The agent appeared safe, with no adverse lab values seen. Headache and pain at the infusion site were the only events reported by participants. ...